about
Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerExpert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UKRole of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agentsImmune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumoursUse of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.Targeted therapies in small cell lung cancer: a reviewThe TORCH trial.Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer.Lung cancer after treatment for breast cancer.Management of small cell lung cancer: recent developments for optimal care.Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.Third-line chemotherapy in small-cell lung cancer: an international analysis.Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?Therapies in the pipeline for small-cell lung cancer.Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line settingAvailability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie.Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.Can EBUS-TBNA provide an accurate diagnosis in patients found to have enlarged or FDG-avid lymph nodes during surveillance of previously treated lung cancer? A retrospective study.Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.Current and future therapeutic approaches for the treatment of small cell lung cancer.Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer.Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.Prise en charge du cancer bronchique à petites cellules (CPC) (localisé et étendu)Outcomes of octogenarian (≥80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie HospitalImmune checkpoint blockade in small cell lung cancerPredictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer
P50
Q26745427-AA890F71-8E6E-4D8C-A2D4-752EFDBFD5DBQ26799390-0D3002B4-FBA0-4F3D-82AD-AC5E41D9FE1EQ27027957-AFD0BE21-D01F-4DE2-BBBD-F5F934E46E78Q28079771-854DFB8E-33FA-40D6-8684-59F675967C60Q33394001-25E0018B-D4A6-4EC2-89B4-0302FB828C30Q33394173-23372BCF-D8C6-46DE-BC9D-8B4CA16AE744Q33394319-A3A7C304-A981-4812-9A2D-4027C445AFF3Q35076234-32FB0465-025D-47C6-833F-ABBB1EC84BF8Q35200333-E9BEE780-96D3-46A8-B893-768E8DBBBF01Q36858092-FDAB6F61-6F00-474B-B964-B8101A974DA0Q37764474-9BA52B4F-D2B8-445F-A381-027F53CFF7C3Q37987205-F3A5E88E-DE64-447C-8E23-033D92CD8301Q38019974-1A96B31F-E8B8-49E2-B779-BB05482F8D25Q38171602-604F8CB5-C9DC-4C8F-AB50-4332900AB64BQ38173439-FC774DED-3EE6-434D-82E0-6E58012AA06BQ38199737-99228490-7D8C-4607-AC09-489B49F3FDDEQ38405836-5EAE9A8C-9CBD-464A-97F1-4167073EE7B2Q38564407-506B246D-3E57-4747-845D-F473232A3938Q38609692-0627B76A-6DF8-4AEB-BDAA-746393DCA11CQ38699858-D6A1223A-E58D-4424-A1B0-27F635241D96Q38821038-E6223C5B-2F4E-4816-A749-1BCC8A8E576DQ38871386-5B70ADE7-2EF3-4908-AE01-ED36786EA68EQ38916160-555FBE2C-18FA-4D6D-A830-A749B04D2789Q39827211-25678A2A-2C98-4147-8CE8-1063D222E724Q41732723-CF8A6901-1237-4605-A75A-01EF5D3B2590Q42275107-E0DC2A3A-EA24-46E7-A4CD-A3DDCEA31680Q43458602-69A3EBA8-8C8E-4E10-989B-77F7FCF4B33EQ43796736-58B6A955-1583-4D2C-B9A2-2772C7E692BDQ44390796-3A948F84-F798-4C71-A085-9EF8E5990716Q46488979-5DAFFF47-740D-47DE-A986-7C613A89270EQ47563553-06300538-BA3E-439B-930B-B2D7AF656076Q50562989-0E509ACD-EC34-4EE2-B90D-CC030AC804FDQ50696633-297349BF-8C4A-43B4-843D-2AD001C82A34Q52653783-B822E93D-C54E-4E3C-8808-0C00A1E24DFDQ55079845-8203A608-C8E8-4865-91C7-CA48A05F3A0CQ55401509-55B5D4E2-3E41-42EF-B2A6-DE22C489EB28Q57569698-420AEEC9-B71C-4333-83B3-B6B4A2FC8A6CQ60620489-75D3C224-3561-4A2B-AD20-0D862181AF9DQ90125406-68C11F62-01CD-4030-BD36-AFC073902F5FQ90354457-90F8BD21-071A-4509-8ACA-C16DC977A916
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raffaele Califano
@ast
Raffaele Califano
@en
Raffaele Califano
@es
Raffaele Califano
@nl
type
label
Raffaele Califano
@ast
Raffaele Califano
@en
Raffaele Califano
@es
Raffaele Califano
@nl
prefLabel
Raffaele Califano
@ast
Raffaele Califano
@en
Raffaele Califano
@es
Raffaele Califano
@nl
P106
P1153
24483067300
P21
P31
P496
0000-0003-2611-5319